Further Understanding of the Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: Implications for Prognosis
Nerina Denaro,Marco Carlo Merlano,Cristiana Lo Nigro
DOI: https://doi.org/10.2147/CMAR.S277907
2021-05-18
Cancer Management and Research
Abstract:Nerina Denaro, 1 Marco Carlo Merlano, 1 Cristiana Lo Nigro 1, 2 1 Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; 2 Central Laboratory, Galliera Hospital, Genoa, Italy Correspondence: Cristiana Lo Nigro Central Laboratory, Galliera Hospital, Via Mura Delle Cappuccine 14, Genoa, 16128, Italy Tel +39 3176219417 Email Purpose: We aimed to review the literature on the tumor microenvironment as a key player in tumor growth and anti-cancer treatment responses in head and neck cancer. Patients and Methods: We reviewed the recent literature on this topic, using the following research words: "tumor microenvironment" and "head and neck cancer or neoplasm or head and neck squamous cell carcinoma" and "immune cells" and "stromal cells". A search was conducted on the PubMed website and reports from international meetings, presentations and abstracts. Results: The tumor microenvironment is a complex network in which myeloid cells, tumoral cells, growth factors and cytokines are involved in angiogenesis, the extracellular matrix and epithelial-to-mesenchymal transition. Conclusion: Immune resistance and rapid tumor growth depend on immunosuppressive and pro-tumoral environments. Further investigations to classify and adequately treat patients with head and neck cancer are required. Keywords: head and neck squamous cell carcinoma, immune microenvironment, prognosis, treatment Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease characterized by different anatomic origins and clinical behavior. In the past few decades, the group of human papilloma virus (HPV)-related cancer has been distinguished from non-virally induced cancer. However, among these groups, there are not yet any reliable molecular biomarkers for distinguishing different subgroups of patients at risk. 1 The tumor microenvironment (TME) is increasingly being appreciated as an important determinant of cancer outcome, including in HNSCC. There is no exhaustive definition of TME, as it involves lymphocytes, fibroblasts, neutrophils, eosinophils, macrophages and myeloid-derived suppressor cells, as well as stromal cells and tumoral cells. These cells interact tightly and dynamically, and the balance of proangiogenic factors, tissue pH, growth factors and cytokine production changes over time. 2 The TME is the result of factors associated with cancer (such as hypoxia, necrosis, mutational load and tumor mutation burden [TMB]) associated with the patient's characteristics (age, viral infection, eg cytomegalovirus [CMV], HPV, Epstein–Barr virus [EBV], smoking, lifestyle, sex, previous or concurrent medication) and immune system/inflammation (eg chronic, acute or no inflammation; CD4 + /CD8 + ratio; T-cell exhaustion) and factors related to geographic origin (ie microbioma, human leukocyte antigen [HLA] polymorphisms). Moreover, the TME may be influenced by anti-cancer treatment (ie chemotherapy: gemcitabine reduces myeloid cells, but has no effect on cytotoxic cells; cyclophosphamide at low doses reduces T-regulatory cells [T-reg], taxanes reduce myeloid cells, interleukin-1 [IL-1] and tumor necrosis factor-β [TNF-β]; radiotherapy). 2 To date, most studies on the predictive markers for response to immunotherapy have focused on protein programmed death ligand-1 (PD-L1) and the TMB, rather than the environment in which the tumor proliferates. However, even though there is a correlation between the high expression of PD-L1 and response, as well as high TMB and response, several other mechanisms can impair the immune response. 3 Recent studies have shown that the TME has a more profound influence on the growth and metastatic spread of HNSCC than was previously appreciated. In HNSCC, tumor–stromal cross-talk is a key step in the pathogenesis of HNSCC. Cancer-associated fibroblasts (CAFs), chemokines, cytokines, and proliferative and inflammatory signal pathways are the major players in this complex network. An active tumor–stromal cross-talk is essential to promote cancer growth and metastization. Pro-tumoral cytokines (eg IL-10 and IL-1) induce interferon-γ (IFN-γ) downregulation, stimulate matrix metalloproteinases [MMPs] (increasing metastatic tumor-cell escape) and participate in angiogenesis. 4 The immune microenvironment is of special interest for its possible implications. Little is known about the characteristics of patients who are more likely to experience a long-term benefit from immune checkpoint inhibitor (ICI) therapy. Figure 1 summarizes the actors involved in -Abstract Truncated-
oncology